Small ubiquitin-like modifier 1 [corrected] mediates the resistance of prosthesis-loosening fibroblast-like synoviocytes against Fas-induced apoptosis by Meinecke, I et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2009
Small ubiquitin-like modifier 1 [corrected] mediates the
resistance of prosthesis-loosening fibroblast-like synoviocytes
against Fas-induced apoptosis
Meinecke, I; Pap, G; Mendoza, H; Drange, S; Ender, S; Strietholt, S; Gay, R E;
Seyfert, C; Ink, B; Gay, S; Pap, T; Peters, M A
Meinecke, I; Pap, G; Mendoza, H; Drange, S; Ender, S; Strietholt, S; Gay, R E; Seyfert, C; Ink, B; Gay, S; Pap, T;
Peters, M A (2009). Small ubiquitin-like modifier 1 [corrected] mediates the resistance of prosthesis-loosening
fibroblast-like synoviocytes against Fas-induced apoptosis. Arthritis and Rheumatism, 60(7):2065-2070.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Arthritis and Rheumatism 2009, 60(7):2065-2070.
Meinecke, I; Pap, G; Mendoza, H; Drange, S; Ender, S; Strietholt, S; Gay, R E; Seyfert, C; Ink, B; Gay, S; Pap, T;
Peters, M A (2009). Small ubiquitin-like modifier 1 [corrected] mediates the resistance of prosthesis-loosening
fibroblast-like synoviocytes against Fas-induced apoptosis. Arthritis and Rheumatism, 60(7):2065-2070.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Arthritis and Rheumatism 2009, 60(7):2065-2070.
Small ubiquitin-like modifier 1 [corrected] mediates the
resistance of prosthesis-loosening fibroblast-like synoviocytes
against Fas-induced apoptosis
Abstract
OBJECTIVE: To study the expression of small ubiquitin-like modifier 1 (SUMO-1) in aseptic loosening
of prosthesis implants and to investigate its role in regulating the susceptibility of prosthesis-loosening
fibroblast-like synoviocytes (FLS) to Fas-induced apoptosis. METHODS: Specimens of aseptically
loosened tissue were obtained at revision surgery, and the expression of SUMO-1 was analyzed by in
situ hybridization. SUMO-1 levels in FLS were determined by quantitative polymerase chain reaction
and Western blot analysis. Immunohistochemistry and confocal microscopy were used to study the
subcellular localization of SUMO-1. The functional role of SUMO-1 in Fas-induced apoptosis of
prosthesis-loosening FLS was investigated by small interfering RNA-mediated knockdown of SUMO-1
and by gene transfer of the nuclear SUMO-specific protease SENP1. RESULTS: SUMO-1 was
expressed strongly in aseptically loosened tissue and was found prominently at sites adjacent to bone.
Prosthesis-loosening FLS expressed levels of SUMO-1 similar to the levels expressed by rheumatoid
arthritis (RA) FLS, with SUMO-1 being found mainly in promyelocytic leukemia protein nuclear
bodies. Knockdown of SUMO-1 had no effect on spontaneous apoptosis but significantly increased the
susceptibility of prosthesis-loosening FLS to Fas-induced apoptosis. Gene transfer of the nuclear
SUMO-specific protease SENP1 reverted the apoptosis-inhibiting effects of SUMO-1. CONCLUSION:
These data suggest that SUMO-1 is involved in the activation of both RA FLS and prosthesis-loosening
FLS by preventing these cells from undergoing apoptosis. Modification of nuclear proteins by SUMO-1
contributes to the antiapoptotic effects of SUMO-1 in prosthesis-loosening FLS, providing evidence for
the specific activation of sumoylation during their differentiation. Therefore, SUMO-1 may be an
interesting target for novel strategies to prevent aseptic prosthesis loosening.
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Abstract 
Objectives: To study the expression of the small ubiquitin-like modifier (SUMO)-1 in 
aseptic loosening (AL) of prosthesis implants and investigate its role in regulating the 
susceptibility of prosthesis loosening fibroblast-like synoviocytes (PL FLS) to Fas-
induced apoptosis.  
Methods: AL tissues were obtained at revision surgery, and the expression of SUMO-1 
was analyzed by in situ hybridization. SUMO-1 levels in fibroblast-like synoviocytes were 
determined by qPCR and Western blot analysis. Immunohistochemistry and confocal 
microscopy served to study the subcellular localization of SUMO-1. The functional role 
of SUMO-1 in Fas-induced apoptosis of PL FLS was investigated by siRNA-mediated 
knockdown of SUMO-1 and by gene transfer of the nuclear specific SUMO-protease 
SENP1.  
Results: SUMO-1 was expressed strongly in AL tissue and was found prominently at 
sites adjacent to bone. PL FLS expressed similar levels of SUMO-1 as RA FLS, with 
SUMO-1 being found mainly in promyelocytic leukaemia (PML) nuclear bodies. 
Knockdown of SUMO-1 had no effects on spontaneous apoptosis but significantly 
increased the susceptibility of PL FLS to Fas-induced apoptosis. Gene transfer of the 
nuclear SUMO- protease SENP1 reverted the apoptosis-inhibiting effects of SUMO-1. 
Conclusions: The data suggest that SUMO-1 is involved in the activation of both RA and 
PL FLS by preventing these cells from apoptosis. The modification of nuclear proteins by 
SUMO-1 contributes to the anti-apoptotic effects of SUMO-1 in PL FLS arguing for the 
specific activation of SUMOylation during their differentiation. Therefore, SUMO-1 may 
be an interesting target for novel strategies to prevent aseptic prosthesis loosening.
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Introduction 
Aseptic prosthesis loosening (AL) of prosthesis implants is a major long-term 
complication of joint replacement surgery. It is characterized by the development and 
destructive growth of a synovium-like membrane (SLIM) at the conjunction between the 
implanted prosthesis and the bone (1, 2). SLIM formation is widely considered a foreign 
body reaction initiated by wear debris particles from the prosthesis. However, the cellular 
and molecular mechanisms that initiate this membrane and promote its growth remain 
incompletely understood. Multiple data suggest that in addition to macrophages, 
fibroblasts of the SLIM play an important role in AL, and there is evidence that the 
synovial membrane in rheumatoid arthritis (RA) and the SLIM share certain similarities 
both in their cellular properties and in their destructive behavior (1-3). Specifically, it has 
been hypothesized that during their differentiation from bone marrow progenitors, 
prosthesis loosening fibroblast-like synoviocytes (PL FLS) acquire features of cellular 
activation that are similar to those seen in rheumatoid arthritis fibroblast-like 
synoviocytes (RA FLS).  
The resistance against apoptosis is one of the hallmarks of RA FLS, and it has been 
shown in different studies that the ability of RA FLS to undergo Fas-induced apoptosis is 
drastically impaired (4). Among the molecules that contribute to the resistance of RA 
FLS, the small ubiquitin-like modifier (SUMO)-1 has become of interest. SUMO-1 can 
covalently modify a variety of proteins and modulates downstream pathways of the Fas 
signaling (5-7). Of interest it was shown recently that SUMO-1 is over expressed in RA 
FLS when compared to osteoarthritic fibroblasts and contributes to the resistance of 
these cells against Fas-induced apoptosis (8). This study demonstrated that rather than 
interfering directly with the Fas-molecule, SUMOylation of the nuclear promyelocytic 
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leukemia (PML) protein and subsequent recruitment of the pro-apoptotic molecule DAXX 
into PML nuclear bodies constitutes the mechanism by which SUMO-1 inhibits Fas-
induced apoptosis in RA FLS.   
So far the question of whether alterations in apoptosis of PL FLS may also contribute to 
the formation and aggressive growth of the SLIM has not been investigated. Therefore, 
we tested if altered SUMO-1 modifications are characteristic of the SLIM around loose 
joint arthroplasties and, through the extension of the life span of SLIM cells, may 
contribute to the membrane formation as well as to its destructive properties.  
Materials and methods 
Patients and samples 
Samples of the SLIM surrounding loose joint arthroplasties were obtained from 13 
patients with failed prosthetic joints (5 knee, 8 hip joints) at revision surgery at the 
Department of Orthopedic Surgery of the University of Magdeburg School of Medicine, 
Magdeburg, Germany and the Department of Orthopedic Surgery, KMG-Kliniken Kyritz, 
Germany. Tissue samples from the loose hip arthroplasties were obtained from the 
proximal area of loose stem components while those from loose knee arthroplasties 
originated from around the loose tibia components. RA FLS were obtained from synovial 
tissues of 11 patients with RA who met the 1987 revised criteria of the American College 
of Rheumatology for the disease (both hip and knee). Parts of the tissue were used for 
primary fibroblast isolation or were embedded into paraffin; FLS were grown in DMEM 
(10% FCS) until passages 4-6 as described (8). Bone marrow stromal cells (BMSC) 
were isolated by gradient centrifugation and plastic adherence. Briefly, cells were 
passed through a 40 µm nylon filter and washed gently with HANKS buffered saline by 
centrifugation at 300 x g for 5 minutes. Cells were subsequently separated by density 
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gradient centrifugation at 300 x g for 20 minutes. Mononuclear interphase cells were 
collected and washed by centrifugation at 300 x g for 5 minutes. Pellets were 
resuspended in DMEM low-glucose (20% FCS). All samples were collected with 
informed consent and ethical approval. 
In situ hybridization 
RNA probes for in situ hybridization were prepared as previously described and labeled 
with digoxigenin-UTP (Boehringer Mannheim). In situ hybridization was performed as 
described by Kriegsmann et al. (9). Hybridised probes were detected using anti-
digoxigenin Fab fragments linked to alkaline phosphatase and NBT/BCIP substrate 
(Boehringer-Mannheim). Negative controls were performed by using the sense probe. 
Expression of SUMO-1 in PL FLS and RA FLS 
Expression of SUMO-1 mRNA in FLS was determined by quantitative PCR (TaqMan, 
Applied Biosystems) using 18S as endogenous control as described previously (8); data 
were calculated with the Ct method. Protein levels were monitored by western blots 
using monoclonal anti-SUMO-1 (clone 21C7, Zymed Laboratories) or anti-beta-actin 
(Sigma-Aldrich) antisera and subcellular distribution was studied using mouse 
monoclonal anti-SUMO-1 (Alexis Biochemicals) and rabbit polyclonal anti-PML (Santa 
Cruz Biotechnology) antisera, visualized with secondary FITC- and TRITC-antisera 
(Jackson ImmunoResearch) as described (8). The experiments were analyzed and 
pictures taken on a confocal microscope (Leica DMIRE2-TCS-SP2). 
Expression vectors, siRNA and transient transfection  
GFP- tagged SENP1wt and SENP1mt expression constructs were generated by PCR, 
subcloned into pEGFP-C1 (Clontech). SUMO-1 siRNA (5’ CUG GGA AUG GAG GAA 
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GAA G 3’) and mismatched, scrambled oligonucleotides (Eurogentec). Transfections 
were performed by AMAXA electroporation as described previously (8).  
Induction and detection of apoptosis 
Apoptosis was induced by incubation 100 ng/ml rhFasL for 16 hours, and cell death was 
determined using a histone fragmentation assay (Cell Death Detection ELISAPlus, 
Roche) as described (8). 
Results 
SUMO-1 is expressed at high levels in PL FLS and found mainly in PML nuclear bodies 
By in situ hybridization, a marked expression of SUMO-1 was found in all investigated 
tissue specimens of AL (Fig. 1a).  SUMO-1 expression was not restricted to areas in 
which debris particles could be seen, and we observed no clear difference in areas with 
differing amounts of such particles (not shown). Interestingly, there was only little 
staining for SUMO-1 at sites of the interface membrane that originally were attached to 
the prosthesis, whereas abundant staining for SUMO-1 was found at sites attached 
directly to bone (Fig 1a). As determined by quantitative real time PCR, PL FLS showed a 
comparable expression of SUMO-1 mRNA as RA FLS (Fig. 1b). Likewise SUMO-1 
protein levels were similar in both cell types (Fig. 1c). In contrast, OA FLS and bone 
marrow stromal cells (BMSC) showed decreased expression of SUMO-1 mRNA (Fig.1b 
and d). Next, we performed immunocytochemistry to study the subcellular distribution. A 
prominent staining for SUMO-1 was found predominantly in the nuclei of PL FLS, and a 
considerable proportion of SUMO-1 was found in association with PML (Fig 1e). We 
detected only a minor expression in the cytoplasm.  
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SUMO-1 mediates the resistance of PL FLS to Fas-induced apoptosis  
Next, we investigated the susceptibility of PL FLS and RA FLS against Fas-induced 
apoptosis. As shown in Fig 2a, there were no differences in spontaneous apoptosis 
between RA FLS and PL FLS. The apoptotic response of PL FLS and RA FLS to 
stimulation with human recombinant FasL (rhFasL) was also similar, demonstrating that 
PL FLS are protected from Fas-induced apoptosis. Although RA FLS showed an even 
lower rate of Fas-induced cell death than PL FLS, these differences were statistically not 
significant, and the susceptibility of both RA FLS and PL FLS to Fas-induced apoptosis 
was much less than that of osteoarthritis synovial fibroblasts reported previously (8). To 
investigate the functional relevance of SUMO-1 for the resistance of PL FLS against 
Fas-induced apoptosis, we used siRNA to knockdown the expression of SUMO-1 in PL 
FLS. As shown in Fig. 2b and c, expression of SUMO-1 mRNA (Fig. 2b) was reduced by 
about 80% in siRNA transfected PL FLS, and Western blot analysis confirmed the 
knockdown of SUMO-1 in these cells (Fig. 2c). siRNA-mediated knockdown of SUMO-1 
in PL FLS clearly sensitized the cells to Fas-induced apoptosis, virtually doubling the 
apoptotic response of PL FLS to rhFasL (Fig. 2d). These effects were SUMO-1 specific, 
because mock siRNA was unable to alter the apoptotic response of PL FLS (Fig. 2d). 
Staurosporin induced apoptosis in more than 90% of the cells after 12 hours with no 
differences between SUMO-1 expressing and silenced cells (not shown). 
Based on our data in RA FLS, we next investigated whether a.) SUMOylation of nuclear 
PML mediates the anti-apoptotic effects of SUMO-1 and b.) de-conjugation of SUMO-1 
from PML by overexpression of the nuclear SUMO- specific protease SENP1 would 
sensitize PL FLS to Fas-induced cell death. To this end, we used two expression 
constructs of SENP1, in which wild type SENP1 (SENP1wt) or a catalytically inactive 
C603A mutant SENP1 (SENP1mt) were fused to green fluorescent protein (GFP). As 
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can be seen in Fig 3a, gene transfer of these constructs into PL FLS resulted in a 
significant overexpression of SENP1wt and SENP1mt. Fluorescence microscopy 
demonstrated that 48 hours after transfection, SENP1 was expressed prominently in the 
nucleus of these cells (Fig. 3b). While gene transfer of either constructs did not alter the 
rate of spontaneous apoptosis, overexpression of SENP1wt most significantly increased 
the susceptibility of PL FLS to Fas-induced cell death (Fig. 3c). Mock vector transfection 
had no effects. Furthermore, the sensitization of PL FLS to Fas-induced apoptosis 
required a functional protease domain, because mutant SENP1 (SENP1mt) was unable 
alter the susceptibility to Fas-induced cell death (Fig. 3c). 
Discussion 
In addition to the regulation of gene transcription and subsequent translation into protein, 
posttranslational protein modification contributes to the modulation of signaling events 
and has gained significant interest over the past years. In this context, the small 
ubiquitin-like modifier (SUMO)-1 is of particular importance, because it covalently binds 
to a number of signaling molecules and, thus, can act as a post-translational regulator of 
different pathways (6). Among those, programmed cell death, appears to be of pivotal 
relevance. We have demonstrated recently that SUMO-1 is upregulated constitutively in 
RA FLS as part of their stable activation and inhibits apoptosis through recruiting pro-
apoptotic molecules such as DAXX into nuclear PML- bodies (8). This is of interest also 
for aseptic prosthesis loosening, because it has been demonstrated that the inflamed 
synovial membrane in RA and the synovial-like interface membrane in aseptic 
prosthesis loosening share some important features (1, 10) and several lines of 
evidence suggest that fibroblast derived form this membrane exhibit an aggressive 
phenotype that is similar to that of RA FLS (11, 12). Therefore, we set out to study the 
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apoptotic response of PL FLS in comparison to RA FLS and investigated whether 
posttranslational modifications by SUMO-1 in a similar way as in RA FLS contributes to 
the resistance of PL FLS to programmed cell death.  In our studies, we first investigated 
the expression of SUMO-1 in SLIM tissues and in PL FLS. We found a strong 
expression mainly in fibroblast-like cells at the SLIM-bone interface and could confirm 
high levels of SUMO-1 in PL FLS by quantitative PCR and Western Blot analysis. The 
high expression of SUMO-1 at the bone-side of the AL membrane supports the 
hypothesis that in addition to wear debris particles and soluble factors such as 
TNFalpha, the interaction of bone marrow progenitor cells with components of the bone 
matrix contributes to their activation and differentiation into the specific phenotype of PL 
FLS. Both the expression levels and the subcellular distribution of SUMO-1 were 
comparable to those in RA FLS (8) suggesting that indeed there are similarities between 
PL FLS and RA FLS and that SUMO-1 may contribute to a reduced susceptibility of PL 
FLS to apoptotic stimuli. In this context, receptor-mediated cell death is of interest, 
because caspase-8 activation has been demonstrated in SLIM tissues (13). Therefore, 
we next analyzed whether increased expression of SUMO-1 functionally regulates the 
response of PL FLS to Fas-induced cell death. In line with our previous data in RA FLS 
(8), knockdown of SUMO-1 by siRNA most strongly sensitized PL FLS to Fas-induced 
apoptosis. To dissect whether direct interaction of SUMO-1 with cytoplasmic proteins is 
responsible for the anti-apoptotic effects of SUMO-1 or whether these effects as in RA 
FLS are due to nuclear SUMOylation events, we used gene transfer of the SUMO- 
specific protease SENP1 that through a single non-consensus nuclear localization signal 
is targeted to the nucleus (14), and mainly removes SUMO-1 from PML nuclear bodies 
(15). Indeed, nuclear expression of functional SENP1 strongly sensitized PL FLS to Fas-
induced apoptosis, while control constructs including a non-functional mutant of SENP1 
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had no effects. These data confirm our observations in RA FLS and suggest that both 
PL FLS and RA FLS are protected from receptor-mediated apoptosis by SUMO-1 in a 
similar fashion.  
All together, our results provide further evidence for similarities between the RA synovial 
membrane and the SLIM by demonstrating that the strong expression of SUMO-1 within 
the SLIM extends the lifespan of the matrix-degrading cells and thereby account for the 
destructive properties. The modification of nuclear proteins by SUMO-1 appears to 
contribute to the anti-apoptotic effects of SUMO-1 in PL FLS arguing for the specific 
activation of nuclear SUMOylation in the course of their differentiation. Therefore, 
SUMO-1 may be interesting target for novel strategies to prevent aseptic prosthesis 
loosening. 
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Figure legends: 
 
Figure 1:  Expression of SUMO-1 in aseptic prosthesis loosening. a) in situ 
hybridization with digoxigenin- labeled RNA probes revealed a strong 
expression of SUMO-1 in serial samples of the synovial-like interface 
membrane around loose joint prostheses. Staining for SUMO-1 was most 
prominent at sites adjacent to bone (black arrows), little staining for SUMO-1 
at sites adjacent to prothesis (white arrows). b and c) comparison of SUMO-
1 levels in prosthesis loosening fibroblast-like synoviocytes (PL FLS), 
rheumatoid arthritis fibroblast-like synoviocytes (RA FLS) and osteoarthritis 
fibroblast-like synoviocytes (OA FLS) revealed similar expression both at the 
mRNA  (b; n≥4; *,P>0.05) and the protein (c) level of PL FLS and OA FLS, 
but significant lower mRNA expression in OA FLS (b) . d) elevated mRNA 
expression of SUMO-1 in prosthesis loosening fibroblast-like synoviocytes 
(PL FLS) compared to bone marrow stromal cells (BMSC) e) in prosthesis 
loosening fibroblast-like synoviocytes, SUMO-1 was found mainly in 
promyelocytic leukaemia nuclear bodies, magnification used 63x. 
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Figure 2:  Inhibition of SUMO-1 sensitizes prosthesis loosening fibroblast-like 
synoviocytes to Fas-induced apoptosis. a) prosthesis loosening 
fibroblast-like synoviocytes showed the same apoptotic response to human 
recombinant Fas-ligand as rheumatoid arthritis fibroblast-like synoviocytes 
(n=11; *, P>0.05). b and c) transfection of prosthesis loosening fibroblast-
like synoviocytes with siRNA against SUMO-1 resulted in a knock-down that 
was detectable both at the mRNA (b) and the protein (c) level. d) siRNA- 
mediated knock-down of SUMO-1 sensitized prosthesis loosening fibroblast-
like synoviocytes to Fas-induced apoptosis, while transfection with mock 
siRNA had no effects (n=3; *,P>0.05).  
 
Figure 3: Overexpression of the nuclear SUMO-protease SENP1 facilitates Fas-
induced apoptosis in prosthesis loosening fibroblast-like 
synoviocytes. a) transfection of prosthesis loosening fibroblast-like 
synoviocytes with the wild type form the nuclear SUMO- protease SENP1 or 
a non-functional mutant of a GFP-tagged SENP1 gene construct resulted a 
significant overexpression of SENP1 at the mRNA level (n≥3). b) when 
investigated at the protein level by fluorescence microscopy, GFP-tagged 
SENP1 was found in the nucleus, magnification used 63x. c) gene transfer 
of the functional wild type form of SENP1 into prosthesis loosening 
fibroblast-like synoviocytes sensitized these cells to Fas-induced cell death, 
while gene transfer of the non-functional mutant or mock transfection had no 
effects (n≥3). 
